A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)

S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Ishiguro, Hiroshi, Saji, Shigehira, Nomura, Shogo, Tanaka, Sunao, Ueno, Takayuki, Onoue, Masahide, Iwata, Hiroji, Yamanaka, Takeharu, Sasaki, Yasutsuna, Toi, Masakazu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727322/
https://ncbi.nlm.nih.gov/pubmed/29131533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1258
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak